Patient Guide: LUT014 completed a Phase 2 double-blind, placebo-controlled, randomized, multisite study to evaluate the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 28 days in colorectal cancer (CRC) patients who developed CTCAE Grade 2 or non-infected Grade 3 EGFRI-induced acneiform lesions after receiving cetuximab or panitumumab (NCT04759664)

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • ✓ Get matched to the right study location for you
  • ✓ Connect directly with study coordinators at multiple participating sites
  • ✓ Understand eligibility with our simplified screening tool
  • ✓ Free service - we're here to help you access clinical research
Trial ID: NCTNCT04759664
Status: COMPLETED_NEXT_PHASE_UPCOMING
Condition: EGFRI-induced acneiform rash
Phase: Phase II

Loading interactive enrollment tools...

The full interactive experience will load momentarily